drugset / Trial / NCT05165849
A Study of GFS101A in Combination With Toripalimab in Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety/tolerability, pharmacokinetics, and efficacy of GFS101A in combination with Toripalimab in patients with advanced solid tumors.
Timeline
- Start
- 2022-04
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
Outcome
Outcome not reported
Stopped: “sponsor decided to withdraw the study”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GFS101A | Unknown | — | Intravenous |
| Background | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |